1. Home
  2. ARBE vs BDSX Comparison

ARBE vs BDSX Comparison

Compare ARBE & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Arbe Robotics Ltd.

ARBE

Arbe Robotics Ltd.

HOLD

Current Price

$0.79

Market Cap

135.0M

Sector

Technology

ML Signal

HOLD

Logo Biodesix Inc.

BDSX

Biodesix Inc.

BUY

Current Price

$18.75

Market Cap

122.0M

Sector

Health Care

ML Signal

BUY

Company Overview

Basic Information
Metric
ARBE
BDSX
Founded
2015
2005
Country
Israel
United States
Employees
N/A
N/A
Industry
EDP Services
Precision Instruments
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
135.0M
122.0M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
ARBE
BDSX
Price
$0.79
$18.75
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
5
Target Price
$2.38
$32.50
AVG Volume (30 Days)
2.5M
129.1K
Earning Date
01-01-0001
05-21-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$88,499,000.00
Revenue This Year
$743.57
$23.35
Revenue Next Year
$326.31
$19.33
P/E Ratio
N/A
N/A
Revenue Growth
N/A
24.08
52 Week Low
$0.76
$0.25
52 Week High
$2.88
$17.40

Technical Indicators

Market Signals
Indicator
ARBE
BDSX
Relative Strength Index (RSI) 32.21 81.53
Support Level N/A $6.33
Resistance Level $1.46 N/A
Average True Range (ATR) 0.08 1.80
MACD -0.02 0.39
Stochastic Oscillator 7.25 97.27

Price Performance

Historical Comparison
ARBE
BDSX

About ARBE Arbe Robotics Ltd.

Arbe Robotics Ltd is a provider of 4D Imaging Radar solutions enabling driver-assist systems while paving the way for fully autonomous driving. It is a research and development company in the field of chips for Advanced radar systems, which are mainly intended to be used as Advanced Driver Assistance Systems (ADAS) adapted for autonomous vehicles as well as for non-automotive uses. Its geographical segments include Sweden, China, Germany, Hong Kong, USA, Israel, Switzerland, Italy, and others.

About BDSX Biodesix Inc.

Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Covid tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.

Share on Social Networks: